Novartis (NOVN SW) Q4 (USD): Core EPS 2.03 (exp. 1.99), Revenue 13.3bln (exp. 13.7bln), guides initial FY26 revenue in the low single digit, core EPS declining by low single digits

CEO:

• "In 2026, we expect to grow through the largest patent expiry in Novartis history, underscoring the strength of our business, and remain well on track to deliver our mid-term guidance.”